Form 8-K - Current report
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
|
| |
| (State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S Employer Identification No.) |
,
,
(Address of principal executive offices) (zip code)
Registrant’s telephone number, including area code: (
)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (seeGeneral Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
(d)On June 18, 2024, the Board of Directors (the “Board”) of Bristol-Myers Squibb Company (the “Company”) elected Mr. Michael R. McMullen to serve as a member of the Board, effective July 1, 2024. The size of the Board was increased to eleven, effective July 1, 2024, in connection with the election of Mr. McMullen.
Mr. McMullen is 63 years old and hasmore than 20 years of executive experience and leadership skills managing large businesses and global operations as well as a proven track record of delivering excellent shareholder returns. During his tenure as CEO, Mr. McMullen led Agilent Technologies, Inc.’s (“Agilent”) transformation into a market leading life-sciences and diagnostics company, nearly tripled its market capitalization, and drove a business and cultural transformation that led to significant improvements in growth and improved profitability.
Mr. McMullen previously served as President and Chief Executive Officer of Agilent from 2015-2024. He is currently serving as a senior advisor to Agilent and its new CEO until October 31, 2024.
Prior to becoming CEO, Mr. McMullen served as Chief Operating Officer from 2014-2015, President of Agilent’s Chemical Analysis Group from 2009-2014 and held roles of increasing responsibilities during 1992-2009, including as Vice President and General Manager of the Chemical Analysis Solutions Unit of the Life Sciences and Chemical Analysis Group and Country Manager for Agilent's China, Japan and Korea Life Sciences and Chemical Analysis Group. He began his career when he joined Agilent’s predecessor, Hewlett-Packard Co., in 1984 as a Financial Analyst. In addition, he currently serves on the board of directors of KLA Corporation and is a former director of Agilent and Coherent, Inc.
Mr. McMullen received his M.B.A. with honors from the University of Pennsylvania’s Wharton School of Business. He received his undergraduate degree, a Bachelor of Science with a double major in finance and economics, magna cum laude from the University of Delaware.
The Board has determined that Mr. McMullen is independent under the New York Stock Exchange Listing Standards and the independence standards adopted by the Board. He will serve as a member of the Audit Committee, effective July 1, 2024.
There are no arrangements or understandings between Mr. McMullen and any other persons pursuant to which he was selected as a director. There are no related party transactions between the Company and Mr. McMullen.
Mr. McMullen will receive compensation for his service on the Board in accordance with the Company’s standard compensatory arrangement for non-employee directors, including an annual retainer of $110,000 and an annual award of deferred share units valued at $210,000 on the date of grant.
A copy of the press release announcing the election of Mr. McMullen is attached to this report as Exhibit 99.1.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
The following exhibits are furnished as part of this Current Report on Form 8-K:
| Exhibit No. | Description | |
| 99.1 | Press release of Bristol-Myers Squibb Company dated June 18, 2024. | |
| 104 | The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| BRISTOL-MYERS SQUIBB COMPANY | |||
| Dated: June 18, 2024 | By: | /s/ Amy Fallone | |
| Name: | Amy Fallone | ||
| Title: | Corporate Secretary | ||
Exhibit 99.1
Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors
(Princeton, N.J., June 18, 2024) –
Bristol Myers Squibb(NYSE: BMY) today announced that its Board of Directors has elected independent director Michael R. McMullen to the Board, effective July 1, 2024. Mr. McMullen will serve as a member of the Audit Committee of the Board of Directors.
“We are pleased to welcome Mr. Michael McMullen to our Board of Directors,” said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squibb. “Mike's extensive experience in managing large businesses and global operations, combined with his proven track record of delivering excellent shareholder returns, will prove valuable as we continue to strengthen the company’s long-term growth profile, progress our pipeline, and prioritize opportunities where we see the highest return for our patients and shareholders.”
Mr. McMullen previously served as president and chief executive officer of Agilent Technologies, Inc. (“Agilent”) from 2015-2024. He brings to the Board more than 20 years of executive experience and leadership skills. During his tenure as CEO, Mr. McMullen led Agilent’s transformation into a market-leading life sciences and diagnostics company, nearly tripled its market capitalization, and drove a business and cultural transformation that led to significant improvements in growth and improved profitability. He is currently serving as a senior advisor to Agilent and its new CEO until October 31, 2024.
Prior to becoming CEO of Agilent, Mr. McMullen served as chief operating officer from 2014-2015, president of Agilent’s Chemical Analysis Group from 2009-2014 and held roles of increasing responsibilities during 1992-2009, including as vice president and general manager of the Chemical Analysis Solutions Unit of the Life Sciences and Chemical Analysis Group and country manager for Agilent's China, Japan and Korea Life Sciences and Chemical Analysis Group. Mr. McMullen began his career when he joined Agilent's predecessor, Hewlett-Packard Co., in 1984 as a financial analyst.
1
Mr. McMullen received his M.B.A. with honors from the University of Pennsylvania’s Wharton School of Business. He received his undergraduate degree, with a double major in finance and economics, magna cum laude from the University of Delaware. Mr. McMullen also serves on the board of directors of KLA Corporation and is a former director of Agilent and Coherent, Inc.
, the Board’s lead independent director, said: “Mike is an accomplished global executive whose transformational success is widely acknowledged by investors and industry experts. His global experience and inspirational leadership style will benefit the company and uniquely position the Board to support the company through its next chapter. We welcome Mike and look forward to his contributions.”
Mr. McMullen commented: “I am pleased to be joining the Board of Bristol Myers Squibb, a company known and respected for its long history of innovation and scientific discovery. It’s an exciting time at Bristol Myers Squibb and I look forward to joining my fellow directors and the management team in helping the company realize the promise of the compelling opportunities ahead.”
With the appointment of Mr. McMullen, effective July 1, 2024, the size of the Board will increase to 11. He will receive compensation in accordance with the company’s director compensation program. For more information about the Bristol Myers Squibb Board of Directors, click here.
About Bristol Myers Squibb Company
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at
BMS.comor follow us on
LinkedIn,
X(formerly Twitter),
YouTube,
Facebook, and
Instagram.
2
corporatefinancial-news
###
For more information, contact:
Media:
media@bms.com
Investors:
investor.relations@bms.com
3
Document and Entity Information | Jun. 18, 2024 |
|---|---|
| Entity Listings [Line Items] | |
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | Jun. 18, 2024 |
| Entity File Number | 001-01136 |
| Entity Registrant Name | BRISTOL-MYERS SQUIBB COMPANY |
| Entity Central Index Key | 0000014272 |
| Entity Incorporation, State or Country Code | DE |
| Entity Tax Identification Number | 22-0790350 |
| Entity Address, Address Line One | Route 206 & Province Line Road |
| Entity Address, City or Town | Princeton |
| Entity Address, State or Province | NJ |
| Entity Address, Postal Zip Code | 08543 |
| City Area Code | 609 |
| Local Phone Number | 252-4621 |
| Entity Emerging Growth Company | false |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Common Stock [Member] | |
| Entity Listings [Line Items] | |
| Title of 12(b) Security | Common Stock, $0.10 Par Value |
| Trading Symbol | BMY |
| Security Exchange Name | NYSE |
| 1.000% Notes due 2025 [Member] | |
| Entity Listings [Line Items] | |
| Title of 12(b) Security | 1.000% Notes due 2025 |
| Trading Symbol | BMY25 |
| Security Exchange Name | NYSE |
| 1.750% Notes due 2035 [Member] | |
| Entity Listings [Line Items] | |
| Title of 12(b) Security | 1.750% Notes due 2035 |
| Trading Symbol | BMY35 |
| Security Exchange Name | NYSE |
| Celgene Contingent Value Rights [Member] | |
| Entity Listings [Line Items] | |
| Title of 12(b) Security | Celgene Contingent Value Rights |
| Trading Symbol | CELG RT |
| Security Exchange Name | NYSE |
Bristol Myers Squibb (PK) (USOTC:BMYMP)
Historical Stock Chart
From May 2024 to Jun 2024
Bristol Myers Squibb (PK) (USOTC:BMYMP)
Historical Stock Chart
From Jun 2023 to Jun 2024
 | {{bbMessage.M_Alias}}{{bbMessage.MSG_Date}}{{bbMessage.HowLongAgo}}{{bbMessage.MSG_ID}}{{bbMessage.MSG_Subject}} |
Loading Messages....
Bristol Myers Squibb Company (PK) News
Loading Messages....
`,data() {return {tabs: [] };},created() {this.tabs = this.$children;},methods: {selectTab(selectedTab) {this.tabs.forEach(tab => {tab.isActive = (tab.name == selectedTab.name);});}}});Vue.component('tab', {template: `
`,props: {name: { required: true },selected: { default: false}},data() {return {isActive: false};},computed: {href() {return '#' + this.name.toLowerCase().replace(/ /g, '-');}},mounted() {this.isActive = this.selected;}});Vue.component('newslist', {template: `
FEATURED
•{{ article.source }} • {{ article.date}} {{article.time}}
`,props: {source: { required: true },rawarticles: { required: true },limit: { default: 12 }},methods: {processData: function(articles){if(articles.length > this.limit){articles = articles.slice(0, this.limit);}this.articles = articles;this.loaded = true;Vue.nextTick(function(){});},stripRedudancies: function(articles){return _.uniqBy(articles, "headline");}},data() {return {loaded: false,articles: []};},mounted() {this.processData(this.rawarticles);}});new Vue({el: '#nw-news-widget',data: {loaded: false,availableTabs: {"Press Releases": [{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/USOTC\/bristol-myers-squibb-pk-BMYMP\/stock-news\/94065940\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1718742180,"date":"Tue Jun 18, 2024 ","time":"4:23 PM (1 week ago)","full_date":"June 18, 2024 4:23 PM","post_time":"June 18 2024","article_id":94065940,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/USOTC\/bristol-myers-squibb-pk-BMYMP\/stock-news\/93819129\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1715287987,"date":"Thu May 09, 2024 ","time":"4:53 PM (2 months ago)","full_date":"May 9, 2024 4:53 PM","post_time":"May 09 2024","article_id":93819129,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 424B5 - Prospectus [Rule 424(b)(5)]","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/USOTC\/bristol-myers-squibb-pk-BMYMP\/stock-news\/93305067\/form-424b5-prospectus-rule-424b5","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1708119259,"date":"Fri Feb 16, 2024 ","time":"4:34 PM (4 months ago)","full_date":"February 16, 2024 4:34 PM","post_time":"February 16 2024","article_id":93305067,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form SC TO-T\/A - Tender offer statement by Third Party: [Amend]","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/USOTC\/bristol-myers-squibb-pk-BMYMP\/stock-news\/93303346\/form-sc-to-t-a-tender-offer-statement-by-third-p","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1708101391,"date":"Fri Feb 16, 2024 ","time":"11:36 AM (4 months ago)","full_date":"February 16, 2024 11:36 AM","post_time":"February 16 2024","article_id":93303346,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/USOTC\/bristol-myers-squibb-pk-BMYMP\/stock-news\/93293799\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1708034259,"date":"Thu Feb 15, 2024 ","time":"4:57 PM (4 months ago)","full_date":"February 15, 2024 4:57 PM","post_time":"February 15 2024","article_id":93293799,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/USOTC\/bristol-myers-squibb-pk-BMYMP\/stock-news\/93281730\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1707946348,"date":"Wed Feb 14, 2024 ","time":"4:32 PM (4 months ago)","full_date":"February 14, 2024 4:32 PM","post_time":"February 14 2024","article_id":93281730,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/USOTC\/bristol-myers-squibb-pk-BMYMP\/stock-news\/93267307\/form-10-k-annual-report-section-13-and-15d-not","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1707843246,"date":"Tue Feb 13, 2024 ","time":"11:54 AM (4 months ago)","full_date":"February 13, 2024 11:54 AM","post_time":"February 13 2024","article_id":93267307,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 424B2 - Prospectus [Rule 424(b)(2)]","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/USOTC\/bristol-myers-squibb-pk-BMYMP\/stock-news\/93265140\/form-424b2-prospectus-rule-424b2","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1707829250,"date":"Tue Feb 13, 2024 ","time":"8:00 AM (4 months ago)","full_date":"February 13, 2024 8:00 AM","post_time":"February 13 2024","article_id":93265140,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form SC TO-T\/A - Tender offer statement by Third Party: [Amend]","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/USOTC\/bristol-myers-squibb-pk-BMYMP\/stock-news\/93255502\/form-sc-to-t-a-tender-offer-statement-by-third-p","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1707741251,"date":"Mon Feb 12, 2024 ","time":"7:34 AM (4 months ago)","full_date":"February 12, 2024 7:34 AM","post_time":"February 12 2024","article_id":93255502,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 4 - Statement of changes in beneficial ownership of securities","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/USOTC\/bristol-myers-squibb-pk-BMYMP\/stock-news\/93211015\/form-4-statement-of-changes-in-beneficial-owners","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1707179591,"date":"Mon Feb 05, 2024 ","time":"7:33 PM (5 months ago)","full_date":"February 5, 2024 7:33 PM","post_time":"February 05 2024","article_id":93211015,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 4 - Statement of changes in beneficial ownership of securities","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/USOTC\/bristol-myers-squibb-pk-BMYMP\/stock-news\/93211012\/form-4-statement-of-changes-in-beneficial-owners","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1707179463,"date":"Mon Feb 05, 2024 ","time":"7:31 PM (5 months ago)","full_date":"February 5, 2024 7:31 PM","post_time":"February 05 2024","article_id":93211012,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 4 - Statement of changes in beneficial ownership of securities","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/USOTC\/bristol-myers-squibb-pk-BMYMP\/stock-news\/93210997\/form-4-statement-of-changes-in-beneficial-owners","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1707179367,"date":"Mon Feb 05, 2024 ","time":"7:29 PM (5 months ago)","full_date":"February 5, 2024 7:29 PM","post_time":"February 05 2024","article_id":93210997,"source_id":"edgar2","media_url":null,"press_release":true}],"All News": [{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/USOTC\/bristol-myers-squibb-pk-BMYMP\/stock-news\/94065940\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1718742180,"date":"Tue Jun 18, 2024 ","time":"4:23 PM (1 week ago)","full_date":"June 18, 2024 4:23 PM","post_time":"June 18 2024","article_id":94065940,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/USOTC\/bristol-myers-squibb-pk-BMYMP\/stock-news\/93819129\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1715287987,"date":"Thu May 09, 2024 ","time":"4:53 PM (2 months ago)","full_date":"May 9, 2024 4:53 PM","post_time":"May 09 2024","article_id":93819129,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 424B5 - Prospectus [Rule 424(b)(5)]","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/USOTC\/bristol-myers-squibb-pk-BMYMP\/stock-news\/93305067\/form-424b5-prospectus-rule-424b5","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1708119259,"date":"Fri Feb 16, 2024 ","time":"4:34 PM (4 months ago)","full_date":"February 16, 2024 4:34 PM","post_time":"February 16 2024","article_id":93305067,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form SC TO-T\/A - Tender offer statement by Third Party: [Amend]","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/USOTC\/bristol-myers-squibb-pk-BMYMP\/stock-news\/93303346\/form-sc-to-t-a-tender-offer-statement-by-third-p","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1708101391,"date":"Fri Feb 16, 2024 ","time":"11:36 AM (4 months ago)","full_date":"February 16, 2024 11:36 AM","post_time":"February 16 2024","article_id":93303346,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/USOTC\/bristol-myers-squibb-pk-BMYMP\/stock-news\/93293799\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1708034259,"date":"Thu Feb 15, 2024 ","time":"4:57 PM (4 months ago)","full_date":"February 15, 2024 4:57 PM","post_time":"February 15 2024","article_id":93293799,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/USOTC\/bristol-myers-squibb-pk-BMYMP\/stock-news\/93281730\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1707946348,"date":"Wed Feb 14, 2024 ","time":"4:32 PM (4 months ago)","full_date":"February 14, 2024 4:32 PM","post_time":"February 14 2024","article_id":93281730,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/USOTC\/bristol-myers-squibb-pk-BMYMP\/stock-news\/93267307\/form-10-k-annual-report-section-13-and-15d-not","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1707843246,"date":"Tue Feb 13, 2024 ","time":"11:54 AM (4 months ago)","full_date":"February 13, 2024 11:54 AM","post_time":"February 13 2024","article_id":93267307,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 424B2 - Prospectus [Rule 424(b)(2)]","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/USOTC\/bristol-myers-squibb-pk-BMYMP\/stock-news\/93265140\/form-424b2-prospectus-rule-424b2","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1707829250,"date":"Tue Feb 13, 2024 ","time":"8:00 AM (4 months ago)","full_date":"February 13, 2024 8:00 AM","post_time":"February 13 2024","article_id":93265140,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form SC TO-T\/A - Tender offer statement by Third Party: [Amend]","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/USOTC\/bristol-myers-squibb-pk-BMYMP\/stock-news\/93255502\/form-sc-to-t-a-tender-offer-statement-by-third-p","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1707741251,"date":"Mon Feb 12, 2024 ","time":"7:34 AM (4 months ago)","full_date":"February 12, 2024 7:34 AM","post_time":"February 12 2024","article_id":93255502,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 4 - Statement of changes in beneficial ownership of securities","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/USOTC\/bristol-myers-squibb-pk-BMYMP\/stock-news\/93211015\/form-4-statement-of-changes-in-beneficial-owners","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1707179591,"date":"Mon Feb 05, 2024 ","time":"7:33 PM (5 months ago)","full_date":"February 5, 2024 7:33 PM","post_time":"February 05 2024","article_id":93211015,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 4 - Statement of changes in beneficial ownership of securities","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/USOTC\/bristol-myers-squibb-pk-BMYMP\/stock-news\/93211012\/form-4-statement-of-changes-in-beneficial-owners","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1707179463,"date":"Mon Feb 05, 2024 ","time":"7:31 PM (5 months ago)","full_date":"February 5, 2024 7:31 PM","post_time":"February 05 2024","article_id":93211012,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 4 - Statement of changes in beneficial ownership of securities","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/USOTC\/bristol-myers-squibb-pk-BMYMP\/stock-news\/93210997\/form-4-statement-of-changes-in-beneficial-owners","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1707179367,"date":"Mon Feb 05, 2024 ","time":"7:29 PM (5 months ago)","full_date":"February 5, 2024 7:29 PM","post_time":"February 05 2024","article_id":93210997,"source_id":"edgar2","media_url":null,"press_release":true}],"Preferred Contributors": ""}},created: function () {this.loaded = true;Vue.nextTick(function(){});}});});
More Bristol Myers Squibb Company (PK) News Articles
